ΦΑΡΜΑΚΟΓΕΝΕΤΙΚΟΙ ΕΛΕΓΧΟΙ
1. Deepak Voora, Geoffrey S. Ginsburg: Clinical Application of Cardiovascular Pharmacogenetics; Journal of the American College of Cardiology, Volume 60, Issue 1, 3 July 2012, pages 9-20 http://www.sciencedirect.com/science/article/pii/S0735109712013162
2. EUROPEAN MEDICINES AGENCY (EMA): Workshop on pharmacogenomics: from science to clinical care; http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/11/WC500134968.pdf
3. EUROPEAN MEDICINES AGENCY (EMA): Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090323.pdf
4. Kitzmiller, Joseph P., Groen, David K., Phelps, Mitch A., Sadee, Wolfgang: Pharmacogenomic testing: Relevance in medical practice. Why drugs work in some patients but not in others; Cleveland Clinic Journal of Medicine April 2011 vol. 78 4 243- 257 doi: 10.3949/ccjm.78a.10145 http://www.ccjm.org/content/78/4/243.long
5. Mega, Jessica L. et al: Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients with Stable Cardiovascular Disease; JAMA. 2011; 306(20):2221-2228. doi:10.1001/jama.2011.1703 http://jama.jamanetwork.com/article.aspx?articleid=1104664
6. PharmGKB: Clinical Pharmacogenetics Implementation Consortium (CPIC); http://www.pharmgkb.org/page/cpic
7. Schildcrout J.S. et al: Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping; Clin Pharmacol Ther. 2012 Aug; 92(2):235- 42. doi: 10.1038/clpt.2012.66. e-pub 2012 Jun 27 http://www.ncbi.nlm.nih.gov/pubmed/22739144
8. SEARCH Collaborative Group, Link E et al: SLCO1B1 variants and statin-induced myopathy--a genomewide study; N Engl J Med. 2008 Aug 21;359(8):789-99. http://www.nejm.org/doi/full/10.1056/NEJMoa0801936
9. U.S. Food and Drug Administration (FDA): Drug genomics; http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics
10. Wilke R.A. et al: The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy; Clin Pharmacol Ther. 2012 July; 92(1): 112–117. doi:10.1038/ clpt.2012.57 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384438/
11. Zhang, Jian-Ping and Malhorta, Anil K.: Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction; Expert Opinion on Drug Metabolism & Toxicology, January 2011, Vol. 7, No. 1: pages 9-37 doi: 10.1517/17425255.2011.532787 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057913/